Skip to main content
Top
Published in: AIDS and Behavior 1/2019

01-01-2019 | Original Paper

Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies

Authors: Wutyi S. Aung, Rahul P. Bakshi, Jennifer Breakey, James E. Johnson, Craig W. Hendrix, Ethel Weld, Edward J. Fuchs, Mark A. Marzinke

Published in: AIDS and Behavior | Issue 1/2019

Login to get access

Abstract

Evaluating the efficacy of any HIV prevention strategy is dependent on ensuring and objectively monitoring adherence to the intervention. Medicated rectal enemas are a potential method for providing topical, episodic HIV prophylaxis during receptive anal intercourse. Assessing adherence to recommended enema dosing regimens is essential in evaluating the utility of this strategy. We utilized fecal coliform bacteria on used enema tips as a marker for enema use. Enema tip coliforms were tested by repurposing a microtiter plate-based water quality test designed to detect fecal contamination of water. Coliform detection occurred with 100% sensitivity and specificity when tips were assayed on day of use. The assay performed well post-7 day sample storage at room temperature, yielding a sensitivity of 80% and specificity of 93%. All (n = 64) samples collected in a subset of the DREAM-01 rectal microbicide enema clinical trial tested positive, even when tips were evaluated > 7 days post-reported use. The coliform-based enema tip assay allows monitoring of adherence in interventions involving rectal enemas in a sensitive, specific and inexpensive manner. The test performs well in clinical trial settings.
Literature
2.
go back to reference Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
4.
go back to reference Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
5.
go back to reference Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):S55–60.CrossRefPubMedPubMedCentral Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):S55–60.CrossRefPubMedPubMedCentral
8.
go back to reference Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.CrossRefPubMedPubMedCentral Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.CrossRefPubMedPubMedCentral
9.
go back to reference Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–55.CrossRefPubMedPubMedCentral Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–55.CrossRefPubMedPubMedCentral
10.
go back to reference Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retrovir. 2016;32(1):32–43.CrossRefPubMedPubMedCentral Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retrovir. 2016;32(1):32–43.CrossRefPubMedPubMedCentral
12.
go back to reference Abaasa A, Hendrix C, Gandhi M, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73.CrossRefPubMed Abaasa A, Hendrix C, Gandhi M, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22(4):1165–73.CrossRefPubMed
13.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
14.
go back to reference Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1 infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRefPubMed Podsadecki TJ, Vrijens BC, Tousset EP, et al. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1 infected patients. HIV Clin Trials. 2008;9(4):238–46.CrossRefPubMed
16.
go back to reference Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335–42.CrossRefPubMed Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016;213(3):335–42.CrossRefPubMed
18.
go back to reference Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–6.CrossRefPubMed Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53–6.CrossRefPubMed
19.
go back to reference Katzen LL, Fernandez-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050–5.CrossRefPubMedPubMedCentral Katzen LL, Fernandez-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050–5.CrossRefPubMedPubMedCentral
20.
go back to reference Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335–40.CrossRefPubMed Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335–40.CrossRefPubMed
21.
go back to reference Hemmerling A, Harrison WG, Brown JM, et al. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012;39(9):710–2.CrossRefPubMedPubMedCentral Hemmerling A, Harrison WG, Brown JM, et al. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012;39(9):710–2.CrossRefPubMedPubMedCentral
22.
go back to reference Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368–71.CrossRefPubMedPubMedCentral Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368–71.CrossRefPubMedPubMedCentral
23.
go back to reference Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.CrossRefPubMedPubMedCentral Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.CrossRefPubMedPubMedCentral
24.
go back to reference Carballo-Diéguez A, Lentz C, Giguere R, et al. Rectal douching associated with receptive anal intercourse: a literature review. AIDS Behav. 2018;22(4):1288–94.CrossRefPubMedPubMedCentral Carballo-Diéguez A, Lentz C, Giguere R, et al. Rectal douching associated with receptive anal intercourse: a literature review. AIDS Behav. 2018;22(4):1288–94.CrossRefPubMedPubMedCentral
25.
go back to reference Weld ED, Fuchs E, Marzinke M, et al. Tenofovir enema as HIV PrEP for receptive anal intercourse: safety, pharmacokinetics, pharmacodynamics and acceptability (DREAM-01) [5647]. Presented at: 9th International AIDS Society Conference on HIV Science; Paris, 2017. Weld ED, Fuchs E, Marzinke M, et al. Tenofovir enema as HIV PrEP for receptive anal intercourse: safety, pharmacokinetics, pharmacodynamics and acceptability (DREAM-01) [5647]. Presented at: 9th International AIDS Society Conference on HIV Science; Paris, 2017.
26.
go back to reference Bluewater Biosciences, Inc., ON, Canada. ColiplateTM A quantitative 24-hour test for Coliforms and E. Coli manual. Bluewater Biosciences, Inc., ON, Canada. ColiplateTM A quantitative 24-hour test for Coliforms and E. Coli manual.
28.
go back to reference Lifshitz R, Joshi R. Comparison of the novel Coliplate kit and the standard membrane filter technique for enumerating total coliforms and Escherichia coli bacteria in water. Environ Toxicol Water Quality. 1997;13:157–64.CrossRef Lifshitz R, Joshi R. Comparison of the novel Coliplate kit and the standard membrane filter technique for enumerating total coliforms and Escherichia coli bacteria in water. Environ Toxicol Water Quality. 1997;13:157–64.CrossRef
Metadata
Title
Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies
Authors
Wutyi S. Aung
Rahul P. Bakshi
Jennifer Breakey
James E. Johnson
Craig W. Hendrix
Ethel Weld
Edward J. Fuchs
Mark A. Marzinke
Publication date
01-01-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 1/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2211-5

Other articles of this Issue 1/2019

AIDS and Behavior 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.